Lutathera Approved for Children With Gastroenteropancreatic Neuroendocrine Tumors
The FDA has expanded the approval of Lutathera (lutetium Lu 177 dotatate) to include pediatric patients with SSTR-positive GEP-NETs.
Source: empr.com
Theodore Laetsch News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Theodore Laetsch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Theodore Laetsch Today - Breaking & Trending Today
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric and adult patients Gastroenteropancreatic neuroendocrine...
Source: marketscreener.com
FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR–positive GEP-NETs.
Source: onclive.com
Novartis radioligand therapy Lutathera® FDA approved as
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17)...
Source: globenewswire.com
FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
Source: pharmacytimes.com